Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position.

Literature DB >> 1999249

Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position.

W H Sawyer¹, B Lammek, A Misicka, M Kruszynski, A Kolodzieczyk, M Manning.

Abstract

Substitution of arginine for glutamine in the 4-position of a vasopressin V1 antagonist has been reported to turn it into an agonist. We resynthesized this 4-arginine analog and synthesized additional cyclic and linear vasopressin antagonists containing a 4-arginine. The presence of a 4-arginine in the resynthesized and new analogs had relatively minor effects on their antivasopressin V1 and V2 antagonistic potencies.

Entities: Chemical Gene Mutation

Mesh：

Substances：

Year: 1991 PMID： 1999249 DOI： 10.1007/bf02041261

Source DB: PubMed Journal: Experientia ISSN： 0014-4754

Keyword Cloud
References

12 in total

1. SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ.

Authors: R B MERRIFIELD
Journal: Biochemistry Date: 1964-09 Impact factor: 3.162

2. Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins.

Authors: W H SAWYER
Journal: Endocrinology Date: 1958-11 Impact factor: 4.736

3. The quantitative assay of vasopressin.

Authors: J DEKANSKI
Journal: Br J Pharmacol Chemother Date: 1952-12

4. No requirements of cyclic conformation of antagonists in binding to vasopressin receptors.

Authors: M Manning; J P Przybylski; A Olma; W A Klis; M Kruszynski; N C Wo; G H Pelton; W H Sawyer
Journal: Nature Date: 1987 Oct 29-Nov 4 Impact factor: 49.962

5. Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects.

Authors: M Manning; L Balaspiri; M Acosta; W H Sawyer
Journal: J Med Chem Date: 1973-09 Impact factor: 7.446

10. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

Authors: M Kruszynski; B Lammek; M Manning; J Seto; J Haldar; W H Sawyer
Journal: J Med Chem Date: 1980-04 Impact factor: 7.446

Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position.

1. SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ.

2. Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins.

3. The quantitative assay of vasopressin.

4. No requirements of cyclic conformation of antagonists in binding to vasopressin receptors.

5. Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects.

6. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin.

7. Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin.

8. Synthesis, antidiuretic and pressor activities of [arginine4]arginine-vasopressin and two related analogues.

9. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

10. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.